Intravenous Immunoglobulin (IVIg) - 2015 Global Strategic Business Report: Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth
DUBLIN, Mar. 19, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/kxb3sr/intravenous) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering.
This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million and in Kilograms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.
Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
The report profiles 25 companies including many key and niche players such as:
- Baxter International, Inc. (US)
- Beijing Tiantan Biological Products Co., Ltd (China)
- Bharat Serums and Vaccines Limited (India)
- Biotest AG (Germany)
- China Biologic Products, Inc (China)
- Guizhou Taibang Biological Products Co., Ltd (China)
- CSL Limited (Australia)
- CSL Behring LLC (US)
- Grifols, S.A (Spain)
- Hualan Biological Engineering Inc. (China)
- Kedrion S.p.A. (Italy)
- LFB Group (France)
- Octapharma AG (Switzerland)
- OMRIX Biopharmaceuticals Ltd (Israel)
- Shanghai RAAS Blood Products Co., Ltd. (China)
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)
Key Topics Covered:
1. INDUSTRY OVERVIEW
- Intravenous Immunoglobulin - A Proliferating Biologic
- List of FDA-Approved and Off-Label Uses of Intravenous Immunoglobulin Therapy
- Regional Market Perspective
- Growth Drivers and Market Challenges
- Competitive Scenario
- IVIg Products Offered by Global Leading Players (2013)
2. MARKET TRENDS
- Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
- Subcutaneous IG Formulations Gain Therapeutic Foothold
- Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead
- IVIg Treatment for Alzheimer's Hindered by Unsuccessful Clinical Trials
- Synthetic Replacements to IVIg Therapy
- IVIg Therapy - Home-based vs. Outpatient Settings
- IVIg Prices to Remain Strong both in the US and Outside the US
- Per Capita Consumption Rate Varies Across Countries
- Baxter's Gammagard, the Leading Immunoglobulin Product in the US
- Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth
- Favorable Reimbursement and High Usage make US the Largest Consumer of Immunoglobulins Worldwide
- Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
- Aging Global Population: Major Opportunity Indicator
- Improving Healthcare Expenditure to Foster Growth
3. PLASMA PROTEINS - AN OVERVIEW
- Plasma Market Witnesses Surging Demand
- Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins
4. THERAPY OVERVIEW
- Immunoglobulins Overview
- IVIg and SCIg: A Face-off!
- Cost of Product and Treatment
- Side-Effects
- Frequency of Treatment
- Safety Considerations
- Patient Response to Treatment Varies
- Site of Care
- IVIg Therapy Introduction
- Intravenous Immunoglobulin
- Mechanism of IVIg Action
- IVIg Dosage and Treatment Response Time
- Common IVIg Intravenous Dosing Recommendations by Indication
- Complications and Side Effects of Using IVIg
- Precautions to be Undertaken
- Intravenous Immunoglobulin - Indications
- FDA Approved Indications for IVIg
- Off-Label Usage of IVIg
- Select Off-Label Indications for IVIg
- Applications by Medical Specialty
- Neurology
- Hematology
- Immunology
- Dermatology
- Nephrology, Rheumatology, Ophthalmology, and Other Diseases
5. REGULATORY APPROVALS
- CSL Behring Obtains EC Marketing Approval for Privigen® for CIDP Patients
- CSL Behring Obtains FDA Approval for Privigen® to Treat PID and ITP
- Biotest Pharmaceuticals Obtains FDA Approval for BIVGAM IVIg
- Baxter Obtains EC Marketing Approval for HyQvia
- Green Cross Receives Approval to Commence Phase III Clinical Trials
- Baxter Bags FDA Approval for GAMMAGARD LIQUID to Treat MMN
6. PRODUCT INNOVATIONS/INTRODUCTIONS
- Octapharma Canada Introduces Octagam®10% in Canada
- Biotest Introduces BIVIgAM in the US
7. RECENT INDUSTRY ACTIVITY
- Emergent BioSolutions Acquires Cangene
- CMS Begins Evaluation of Payment for In-home IVIG Administration
- AxelaCare Acquires SCP Specialty Infusion
- Pfizer to License Gliknik's GL-2045
- Octapharma Completes Phase II Clinical Trial of Octagam 10% for Alzheimer's
- Grifols International Establishes New IVIg Purification Facility in Los Angeles
- Sorrento Therapeutics Secures Global Rights for Using G-MAB® Antibody Library Technology to Produce rIVIg
- Momenta Pharmaceuticals Acquires Sialic Switch Assets of Virdante Pharmaceuticals
- Grifols' AMBAR Study Integrates Therapeutic Plasmapheresis with Alternating Infusion of IVIg and Albumin for Treatment of Alzheimer's Disease
- Biotest Publishes Clinical Trial Data Related to New Investigational IVIg Product
8. FOCUS ON SELECT PLAYERS
9. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 25 (including Divisions/Subsidiaries - 30)
- The United States (10)
- Japan (1)
- Europe (7)
- - France (1)
- - Germany (1)
- - The United Kingdom (1)
- - Italy (1)
- - Spain (1)
- - Rest of Europe (2)
- Asia-Pacific (Excluding Japan) (10)
- Latin America (1)
- Middle East (1)
For more information visit http://www.researchandmarkets.com/research/kxb3sr/intravenous
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article